{"transactions":[{"id":917303,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-05T21:10:06.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":837000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":837000,"derivative":{"exercise_price":2.3,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":837000},"source":{"system":"sec-edgar","filing":"0001824633-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000182463326000002/primarydocument.xml","form_type":"4"}},{"id":1189481,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-27T20:37:44.000Z","date":"2025-03-25","kind":"purchase","planned":false,"acquired":true,"shares":675000,"price":0.6925,"value":467437.5,"ownership":{"direct":true},"balance_after":1999296,"source":{"system":"sec-edgar","filing":"0001562180-25-002778","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002778/primarydocument.xml","form_type":"4"}},{"id":1193099,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-24T21:03:10.000Z","date":"2025-03-21","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.7306,"value":10959.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73 to $0.731, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":1324296,"source":{"system":"sec-edgar","filing":"0001562180-25-002697","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002697/primarydocument.xml","form_type":"4"}},{"id":1193098,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-24T21:03:10.000Z","date":"2025-03-20","kind":"purchase","planned":false,"acquired":true,"shares":5416,"price":0.7294,"value":3950.4304,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7294 to $0.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":1309296,"source":{"system":"sec-edgar","filing":"0001562180-25-002697","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002697/primarydocument.xml","form_type":"4"}},{"id":1198483,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-18T20:27:55.000Z","date":"2025-03-17","kind":"purchase","planned":false,"acquired":true,"shares":9106,"price":0.7499,"value":6828.5894,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7496 to $0.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":1303880,"source":{"system":"sec-edgar","filing":"0001562180-25-002541","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002541/primarydocument.xml","form_type":"4"}},{"id":1198482,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-18T20:27:55.000Z","date":"2025-03-14","kind":"purchase","planned":false,"acquired":true,"shares":29999,"price":0.7544,"value":22631.2456,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7746 to $0.7782, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":1294774,"source":{"system":"sec-edgar","filing":"0001562180-25-002541","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002541/primarydocument.xml","form_type":"4"}},{"id":1205378,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-14T12:02:56.000Z","date":"2025-03-13","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.7164,"value":35820.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6993 to $0.7999, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":1264775,"source":{"system":"sec-edgar","filing":"0001562180-25-002392","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002392/primarydocument.xml","form_type":"4"}},{"id":1205377,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-14T12:02:56.000Z","date":"2025-03-12","kind":"purchase","planned":false,"acquired":true,"shares":47500,"price":0.7104,"value":33744.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.693 to $0.7512, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":1214775,"source":{"system":"sec-edgar","filing":"0001562180-25-002392","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025002392/primarydocument.xml","form_type":"4"}},{"id":1281396,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-05T21:30:20.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":496000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":496000,"derivative":{"exercise_price":1.11,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":496000},"source":{"system":"sec-edgar","filing":"0001562180-25-000955","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025000955/primarydocument.xml","form_type":"4"}},{"id":1313323,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-01-03T12:41:38.000Z","date":"2024-12-31","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.2087,"value":6043.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":142553,"source":{"system":"sec-edgar","filing":"0001562180-25-000031","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025000031/primarydocument.xml","form_type":"4"}},{"id":1318231,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-01-02T21:09:37.000Z","date":"2024-12-30","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.2,"value":12000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":137553,"source":{"system":"sec-edgar","filing":"0001562180-25-000008","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025000008/primarydocument.xml","form_type":"4"}},{"id":1323801,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-12-20T12:33:45.000Z","date":"2024-12-19","kind":"purchase","planned":false,"acquired":true,"shares":6888,"price":0.8879,"value":6115.8552,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":127553,"source":{"system":"sec-edgar","filing":"0001562180-24-008531","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218024008531/primarydocument.xml","form_type":"4"}},{"id":1323800,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-12-20T12:33:45.000Z","date":"2024-12-18","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.9321,"value":93210.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.89 to $1.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":1167275,"source":{"system":"sec-edgar","filing":"0001562180-24-008531","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218024008531/primarydocument.xml","form_type":"4"}},{"id":1602263,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-04T22:59:05.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":425000,"derivative":{"exercise_price":4.59,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001562180-24-002127","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218024002127/primarydocument.xml","form_type":"4"}},{"id":1875866,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-26T20:20:55.000Z","date":"2023-05-25","kind":"purchase","planned":false,"acquired":true,"shares":900,"price":5.31,"value":4779.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":1067275,"source":{"system":"sec-edgar","filing":"0001562180-23-004517","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218023004517/primarydocument.xml","form_type":"4"}},{"id":1875865,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-26T20:20:55.000Z","date":"2023-05-24","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":5.0114,"value":5011.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.99 to $5.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":1066375,"source":{"system":"sec-edgar","filing":"0001562180-23-004517","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218023004517/primarydocument.xml","form_type":"4"}},{"id":1877635,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-05-25T20:03:57.000Z","date":"2023-05-23","kind":"purchase","planned":false,"acquired":true,"shares":11856,"price":5.63,"value":66749.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":1065375,"source":{"system":"sec-edgar","filing":"0001562180-23-004474","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218023004474/primarydocument.xml","form_type":"4"}},{"id":2024319,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-09T21:07:06.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":330000,"derivative":{"exercise_price":7.2,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001562180-23-001166","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218023001166/primarydocument.xml","form_type":"4"}},{"id":2078420,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-12-21T21:08:12.000Z","date":"2022-12-20","kind":"purchase","acquired":true,"shares":19188,"price":5.1306,"value":98445.9528,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":120665,"source":{"system":"sec-edgar","filing":"0001562180-22-008404","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218022008404/primarydocument.xml","form_type":"4"}},{"id":2387338,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-18T00:09:34.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":327900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":327900,"derivative":{"exercise_price":10.58,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":327900},"source":{"system":"sec-edgar","filing":"0001209191-22-011035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919122011035/doc4.xml","form_type":"4"}},{"id":2472853,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2021-12-14T22:36:33.000Z","date":"2021-12-13","kind":"grant","acquired":true,"shares":8000,"price":12.1294,"value":97035.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.01 to $12.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":1053519,"source":{"system":"sec-edgar","filing":"0001209191-21-069547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121069547/doc4.xml","form_type":"4"}},{"id":2626902,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-22T22:16:09.000Z","date":"2021-07-20","kind":"grant","acquired":true,"shares":285800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":285800,"derivative":{"exercise_price":31.23,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":285800},"source":{"system":"sec-edgar","filing":"0001209191-21-047845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121047845/doc4.xml","form_type":"4"}},{"id":3020545,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Series A Preferred Stock","published_at":"2020-09-30T00:06:46.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":32876,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32876},"source":{"system":"sec-edgar","filing":"0001209191-20-052399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052399/doc4.xml","form_type":"4"}},{"id":3020544,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Series A Preferred Stock","published_at":"2020-09-30T00:06:46.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":32876,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32876},"source":{"system":"sec-edgar","filing":"0001209191-20-052399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052399/doc4.xml","form_type":"4"}},{"id":3020543,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Series A Preferred Stock","published_at":"2020-09-30T00:06:46.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":101477,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":101477},"source":{"system":"sec-edgar","filing":"0001209191-20-052399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052399/doc4.xml","form_type":"4"}},{"id":3020542,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-09-30T00:06:46.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":32876,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":551774,"source":{"system":"sec-edgar","filing":"0001209191-20-052399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052399/doc4.xml","form_type":"4"}},{"id":3020541,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-09-30T00:06:46.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":32876,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":551776,"source":{"system":"sec-edgar","filing":"0001209191-20-052399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052399/doc4.xml","form_type":"4"}},{"id":3020540,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67553,"kind":"person","name":"Vaddi Krishna","position":1,"cik":"0001824633","reported_name":"Vaddi Krishna","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2020-09-30T00:06:46.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":101477,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":101477,"source":{"system":"sec-edgar","filing":"0001209191-20-052399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052399/doc4.xml","form_type":"4"}}]}